Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Genor Biopharma Holdings stock

6998.HK
KYG3871A1004
A3C3E0

Price

1.68
Today +/-
-0.00
Today %
-1.09 %
P

Genor Biopharma Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Genor Biopharma Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Genor Biopharma Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Genor Biopharma Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Genor Biopharma Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Genor Biopharma Holdings Stock Price History

DateGenor Biopharma Holdings Price
11/8/20241.68 undefined
11/7/20241.70 undefined
11/6/20241.73 undefined
11/5/20241.71 undefined
11/4/20241.75 undefined
11/1/20241.72 undefined
10/31/20241.70 undefined
10/30/20241.69 undefined
10/29/20241.75 undefined
10/28/20241.76 undefined
10/25/20241.85 undefined
10/24/20241.67 undefined
10/23/20241.67 undefined
10/22/20241.68 undefined
10/21/20241.66 undefined
10/18/20241.70 undefined
10/17/20241.62 undefined
10/16/20241.62 undefined
10/15/20241.65 undefined
10/14/20241.59 undefined

Genor Biopharma Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Genor Biopharma Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Genor Biopharma Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Genor Biopharma Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Genor Biopharma Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Genor Biopharma Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Genor Biopharma Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Genor Biopharma Holdings’s growth potential.

Genor Biopharma Holdings Revenue, EBIT and net profit per share

DateGenor Biopharma Holdings RevenueGenor Biopharma Holdings EBITGenor Biopharma Holdings Net Income
2024e202.31 M undefined-471.15 M undefined-447.81 M undefined
20230 undefined-702.27 M undefined-674.36 M undefined
202215.93 M undefined-782.72 M undefined-730.21 M undefined
20210 undefined-875.41 M undefined-865.22 M undefined
202010.33 M undefined-2.9 B undefined-3.03 B undefined
201913.04 M undefined-520.5 M undefined-522.08 M undefined
20186.88 M undefined-281.64 M undefined-288.08 M undefined

Genor Biopharma Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e
613100150202
-116.67-23.08----
16.6723.0870.00-93.33--
13701400
-281-520-2,902-875-782-702-471
-4,683.33-4,000.00-29,020.00--5,213.33--233.17
-288-522-3,027-865-730-674-447
-81.25479.89-71.42-15.61-7.67-33.68
361.21361.21244.89495.18504.3506.250
-------
Details

Keystats

ⓘ

Revenue and Growth

The Genor Biopharma Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Genor Biopharma Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
201820192020202120222023
           
0.130.252.932.21.591.17
58100000
523.4165.520000
25.2425.2731.4749.6547.45.67
8.093.933.763.761.341.34
0.680.352.962.251.641.17
241.31224.7229.16223.37205.2260.14
000000
47.8564.980.376.1219.627.17
16.0372.5628.31149.29141.4692.28
021.75128.6321.7521.7517.82
00.685.645.736.918.35
305.19384.6472.04476.26394.94205.75
0.990.733.442.732.031.38
           
153967686969
1.461.929.199.299.389.4
-640.04-1,702.57-5,944.49-6,792.63-7,563.84-8,198.82
0-0.22-2.49-2.95-4.34-5.09
000000
0.820.223.242.51.811.19
30.87103.3691.73129.67132.16141.66
9.8840.339.9958.6640.8621.86
49.96204.05101.9687.5680.6162.77
00029.700
8.9612.4115.057.66.763.23
99.66360.12248.73313.19260.4229.53
35.7929.3516.0120.1121.823.92
014.9714.1313.2812.4411.6
28.61102.9357.4623.1515.2211.13
64.4147.2587.5956.5449.4826.65
164.06507.38336.32369.73309.87256.18
0.990.733.582.872.121.45
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Genor Biopharma Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Genor Biopharma Holdings's financial health and stability.

Assets

Genor Biopharma Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Genor Biopharma Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Genor Biopharma Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Genor Biopharma Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20182019202020212022
-288-523-3,036-866-732
3740506053
00000
-41261-21452107
0.040.112.410.13-0.01
72222
00000
-253-110-786-623-577
-29-27-98-71-12
-29-40-98-54-12
0-120170
00000
-38-710117-49
0.370.293.750-0.01
0.350.283.740.02-0.06
13-2-111-2-2
00000
0.060.132.68-0.73-0.61
-282.92-138.48-885.01-695.13-590.56
00000

Genor Biopharma Holdings stock margins

The Genor Biopharma Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genor Biopharma Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genor Biopharma Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Genor Biopharma Holdings's sales revenue. A higher gross margin percentage indicates that the Genor Biopharma Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Genor Biopharma Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Genor Biopharma Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Genor Biopharma Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Genor Biopharma Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Genor Biopharma Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Genor Biopharma Holdings Margin History

Genor Biopharma Holdings Gross marginGenor Biopharma Holdings Profit marginGenor Biopharma Holdings EBIT marginGenor Biopharma Holdings Profit margin
2024e93.83 %-232.88 %-221.35 %
202393.83 %0 %0 %
202293.83 %-4,912.87 %-4,583.32 %
202193.83 %0 %0 %
202074.87 %-28,094.77 %-29,301.15 %
201926.67 %-3,991.86 %-4,004 %
201820.78 %-4,092.42 %-4,185.95 %

Genor Biopharma Holdings Stock Sales Revenue, EBIT, Earnings per Share

The Genor Biopharma Holdings earnings per share therefore indicates how much revenue Genor Biopharma Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Genor Biopharma Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Genor Biopharma Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Genor Biopharma Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Genor Biopharma Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Genor Biopharma Holdings Revenue, EBIT and net profit per share

DateGenor Biopharma Holdings Sales per ShareGenor Biopharma Holdings EBIT per shareGenor Biopharma Holdings Earnings per Share
2024e0.39 undefined0 undefined-0.87 undefined
20230 undefined-1.39 undefined-1.33 undefined
20220.03 undefined-1.55 undefined-1.45 undefined
20210 undefined-1.77 undefined-1.75 undefined
20200.04 undefined-11.85 undefined-12.36 undefined
20190.04 undefined-1.44 undefined-1.45 undefined
20180.02 undefined-0.78 undefined-0.8 undefined

Genor Biopharma Holdings business model

Genor Biopharma Holdings is one of the most popular companies on Eulerpool.com.

Genor Biopharma Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Genor Biopharma Holdings historical P/E ratio, EBIT multiple, and P/S ratio

Genor Biopharma Holdings shares outstanding

The number of shares was Genor Biopharma Holdings in 2023 — This indicates how many shares 506.245 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Genor Biopharma Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Genor Biopharma Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Genor Biopharma Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Genor Biopharma Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Genor Biopharma Holdings.

Genor Biopharma Holdings shareholders

%
Name
Stocks
Change
Date
24.77982 % Hillhouse Capital Management Ltd.127,989,10304/10/2024
7.27214 % Yunnan Walvax Biotechnology Co., Ltd.37,560,998012/31/2023
6.03234 % Temasek Holdings Pte. Ltd.31,157,34809/11/2024
1.34440 % Guo (Feng Ph.D.)6,943,8751,052,5009/3/2024
0.06680 % Weng (Chengyi)345,000345,0009/12/2024
0.00048 % American Century Investment Management, Inc.2,50006/30/2024
0 % State Street Global Advisors (US)0-284,0009/30/2023
1

Genor Biopharma Holdings Executives and Management Board

Dr. Feng Guo(52)
Genor Biopharma Holdings Executive Chairman of the Board, Chief Executive Officer (since 2020)
Compensation 41.2 M
Mr. Wen Chen(53)
Genor Biopharma Holdings Independent non-executive Director
Compensation 420,000
Mr. Edwin Fung(57)
Genor Biopharma Holdings Independent non-executive Director
Compensation 420,000
Mr. Honghao Zhou(82)
Genor Biopharma Holdings Independent non-executive Director
Compensation 420,000
Mr. Wende Chen(58)
Genor Biopharma Holdings Chief Operation Officer
1
2
3
4

Genor Biopharma Holdings Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
G1 Therapeutics Stock
G1 Therapeutics
SupplierCustomer0,420,740,840,850,95
WALVAX A Stock
WALVAX A
SupplierCustomer0,060,56-0,100,680,59
1

Most common questions regarding Genor Biopharma Holdings

What is the P/E ratio of Genor Biopharma Holdings 2024?

The Genor Biopharma Holdings P/E ratio is -1.9.

What is the P/S ratio of Genor Biopharma Holdings 2024?

The Genor Biopharma Holdings P/S ratio is 4.21.

What is the Quality Investing of Genor Biopharma Holdings?

The Quality Investing for Genor Biopharma Holdings is 1/10.

What is the revenue of Genor Biopharma Holdings 2024?

The expected Genor Biopharma Holdings revenue is 202.31 M CNY.

How high is the profit of Genor Biopharma Holdings 2024?

The expected Genor Biopharma Holdings profit is -447.81 M CNY.

What is the business model of Genor Biopharma Holdings

No history available for Genor Biopharma Holdings.

What is the Genor Biopharma Holdings dividend?

Genor Biopharma Holdings pays a dividend of 0 CNY distributed over payouts per year.

How often does Genor Biopharma Holdings pay dividends?

The dividend cannot currently be calculated for Genor Biopharma Holdings or the company does not pay out a dividend.

What is the Genor Biopharma Holdings ISIN?

The ISIN of Genor Biopharma Holdings is KYG3871A1004.

What is the Genor Biopharma Holdings WKN?

The WKN of Genor Biopharma Holdings is A3C3E0.

What is the Genor Biopharma Holdings ticker?

The ticker of Genor Biopharma Holdings is 6998.HK.

How much dividend does Genor Biopharma Holdings pay?

Over the past 12 months, Genor Biopharma Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genor Biopharma Holdings is expected to pay a dividend of 0 CNY.

What is the dividend yield of Genor Biopharma Holdings?

The current dividend yield of Genor Biopharma Holdings is .

When does Genor Biopharma Holdings pay dividends?

Genor Biopharma Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Genor Biopharma Holdings?

Genor Biopharma Holdings paid dividends every year for the past 0 years.

What is the dividend of Genor Biopharma Holdings?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Genor Biopharma Holdings located?

Genor Biopharma Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Genor Biopharma Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Genor Biopharma Holdings from 11/9/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did Genor Biopharma Holdings pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of Genor Biopharma Holdings in the year 2023?

In the year 2023, Genor Biopharma Holdings distributed 0 CNY as dividends.

In which currency does Genor Biopharma Holdings pay out the dividend?

The dividends of Genor Biopharma Holdings are distributed in CNY.

All fundamentals about Genor Biopharma Holdings

Our stock analysis for Genor Biopharma Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genor Biopharma Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.